These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 24071539)
1. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. Michallet AS; Cazin B; Bouvet E; Oberic L; Schlaifer D; Mosser L; Salles G; Coiffier B; Laurent G; Ysebaert L J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539 [TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Ladyzynski P; Molik M; Foltynski P Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118 [TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847 [TBL] [Abstract][Full Text] [Related]
4. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A; Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442 [TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003 [TBL] [Abstract][Full Text] [Related]
7. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702 [TBL] [Abstract][Full Text] [Related]
8. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474 [TBL] [Abstract][Full Text] [Related]
9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Robak T; Lech-Maranda E; Robak P Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624 [TBL] [Abstract][Full Text] [Related]
10. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923 [TBL] [Abstract][Full Text] [Related]
11. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Fornecker LM; Aurran-Schleinitz T; Michallet AS; Cazin B; Guieze R; Dilhuydy MS; Zini JM; Tomowiak C; Lepretre S; Cymbalista F; Brion A; Feugier P; Delmer A; Leblond V; Ysebaert L Am J Hematol; 2015 Jun; 90(6):511-4. PubMed ID: 25752923 [TBL] [Abstract][Full Text] [Related]
12. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T; Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437 [TBL] [Abstract][Full Text] [Related]
13. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678 [TBL] [Abstract][Full Text] [Related]
14. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. Panovská A; Smolej L; Lysák D; Brychtová Y; Šimkovič M; Motyčková M; Vodárek P; Lindtnerová M; Trbušek M; Malčíková J; Pospíšilová Š; Mayer J; Doubek M Eur J Haematol; 2013 Jun; 90(6):479-85. PubMed ID: 23506191 [TBL] [Abstract][Full Text] [Related]
15. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgård S; Kimby E; Norin S; Andersson PO; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Österborg A; Hansson L Haematologica; 2019 Apr; 104(4):797-804. PubMed ID: 30467205 [TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia]. Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746 [TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Main C; Pitt M; Moxham T; Stein K Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488 [TBL] [Abstract][Full Text] [Related]
18. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis. Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia]. Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392 [TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]